NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has reached the halfway mark for total enrollment in the second pivotal phase 3 trial of plecanatide in patients with chronic idiopathic constipation (CIC). The trial is currently being conducted at 180 sites and has randomized over 675 CIC patients. This is the second of two ongoing phase 3 pivotal trials designed to confirm the efficacy and safety of both 3.0 mg and 6.0 mg plecanatide once-daily oral tablet versus placebo in patients with CIC. Synergy announced it had achieved the halfway mark for total enrollment in the first phase 3 CIC trial in July 2014. The Company plans to release top-line data from the first phase 3 CIC trial in the second quarter of 2015 and top-line data from the second study in the third quarter of 2015.
Help employers find you! Check out all the jobs and post your resume.
